GlassScriptPhysician profile
Jennifer Brown
NPI 1538203054
$2,218.93
in general payments reported to CMS, 2019-2025
23 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $144 · 2021: $192 · 2022: $474 · 2023: $437 · 2024: $516 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $405.13 | 2019-2024 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $275.95 | 2019-2023 | Linzess |
| Celgene Corporation | $266.87 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $248.99 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $171.18 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Janssen Biotech, INC. | $163.34 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $115.19 | 2019-2024 | |
| Abbvie INC. | $101.34 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $97.94 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $85.32 | 2019-2022 | |
| Madrigal Pharmaceuticals | $43.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $38.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $27.89 | 2022-2023 | Dificid |
| Alfasigma USA, INC. | $26.22 | 2022 | |
| Boston Scientific Corporation | $22.27 | 2023 | Compliance Endokit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $20.91 | 2020 | |
| Braintree Laboratories, INC. | $17.56 | 2025 | Suflave |
| Vivus LLC | $17.54 | 2024 | Qsymia |
| Novo Nordisk INC | $15.85 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $14.97 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $14.10 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.94 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.